HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis.

AbstractBACKGROUND:
Nonselective beta-adrenergic blockers decrease portal pressure and prevent variceal hemorrhage. Their effectiveness in preventing varices is unknown.
METHODS:
We randomly assigned 213 patients with cirrhosis and portal hypertension (minimal hepatic venous pressure gradient [HVPG] of 6 mm Hg) to receive timolol, a nonselective beta-blocker (108 patients), or placebo (105 patients). The primary end point was the development of gastroesophageal varices or variceal hemorrhage. Endoscopy and HVPG measurements were repeated yearly.
RESULTS:
During a median follow-up of 54.9 months, the rate of the primary end point did not differ significantly between the timolol group and the placebo group (39 percent and 40 percent, respectively; P=0.89), nor were there significant differences in the rates of ascites, encephalopathy, liver transplantation, or death. Serious adverse events were more common among patients in the timolol group than among those in the placebo group (18 percent vs. 6 percent, P=0.006). Varices developed less frequently among patients with a baseline HVPG of less than 10 mm Hg and among those in whom the HVPG decreased by more than 10 percent at one year and more frequently among those in whom the HVPG increased by more than 10 percent at one year.
CONCLUSIONS:
Nonselective beta-blockers are ineffective in preventing varices in unselected patients with cirrhosis and portal hypertension and are associated with an increased number of adverse events. (ClinicalTrials.gov number, NCT00006398.)
AuthorsRoberto J Groszmann, Guadalupe Garcia-Tsao, Jaime Bosch, Norman D Grace, Andrew K Burroughs, Ramon Planas, Angels Escorsell, Juan Carlos Garcia-Pagan, David Patch, Daniel S Matloff, Hong Gao, Robert Makuch, Portal Hypertension Collaborative Group
JournalThe New England journal of medicine (N Engl J Med) Vol. 353 Issue 21 Pg. 2254-61 (Nov 24 2005) ISSN: 1533-4406 [Electronic] United States
PMID16306522 (Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, N.I.H., Extramural)
CopyrightCopyright 2005 Massachusetts Medical Society.
Chemical References
  • Adrenergic beta-Antagonists
  • Timolol
Topics
  • Adrenergic beta-Antagonists (adverse effects, therapeutic use)
  • Adult
  • Double-Blind Method
  • Esophageal and Gastric Varices (etiology, prevention & control)
  • Female
  • Gastrointestinal Hemorrhage (etiology, prevention & control)
  • Heart Rate (drug effects)
  • Humans
  • Hypertension, Portal (complications, drug therapy, physiopathology)
  • Liver Cirrhosis (complications)
  • Male
  • Middle Aged
  • Timolol (adverse effects, therapeutic use)
  • Treatment Failure

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: